How to use price transparency data in healthcare M&A due diligence

The revenue a target practice reports tells you what it collects today. Payor rate data tells you what it should be collecting — and what you can unlock post-acquisition.

Healthcare M&A due diligence has historically focused on financial performance, patient volume, and operational quality. These remain essential. But there is a dimension of deal analysis that most acquirers have only recently begun to apply with rigor: understanding the target practice's payor contract position relative to the market — and modeling what that position means for revenue under new ownership.

For PE-backed roll-ups, health systems building outpatient networks, and large groups pursuing strategic acquisitions, this analysis has become one of the most valuable inputs in the due diligence process. Here is why it matters and how to apply it.

The problem with relying on historical financials alone

Consider two scenarios:

• Scenario A: The target practice has above-market rates with its major payors — rates the current ownership negotiated effectively years ago. Revenue is strong, but rate upside is limited. The acquisition price should reflect this ceiling.
• Scenario B: The target practice has below-market rates — either because ownership never pushed hard in negotiations, or because the practice joined a payor network at street rates and never revisited. Revenue appears stable, but it is structurally depressed. A buyer who can renegotiate those contracts post-acquisition is acquiring not just the current revenue stream, but the opportunity to significantly improve it.

Without payor rate benchmarking as part of the due diligence process, there is no reliable way to distinguish between these two scenarios.

What the analysis looks like in practice

A payor rate due diligence analysis for a healthcare acquisition typically covers the following:

Rate position by code and payor

For the target practice's highest-revenue CPT codes, where do their contracted rates sit relative to comparable practices in the same market? Which payors are paying above market, at market, or below market? This creates a code-by-payor heat map of rate position — the foundation for everything that follows.

Revenue uplift modeling

Based on the rate gap analysis, what is the estimated revenue impact of bringing below-market contracts up to market rates? This is not speculative — it is grounded in rates that are already being paid to comparable practices in the same geography by the same payors. The uplift potential becomes a concrete input to deal modeling.

Contract timeline mapping

When do the target's major payor contracts expire? Which renegotiation windows are open in the 12 to 24 months post-close? This determines when the rate improvement opportunity can actually be realized and should be reflected in the financial projections used to underwrite the deal.

Market rate trajectory

Are rates for this specialty in this market trending up or down? Are certain payors consistently paying more than others across the competitive set? Understanding the direction of travel — not just the current snapshot — informs how aggressively to pursue specific contracts post-acquisition.

A GROWING APPLICATION IN PE-BACKED HEALTHCARE 
Private equity firms building specialty roll-up platforms have begun incorporating payor rate analysis as a standard diligence workstream — both for individual acquisitions and for understanding platform-level rate improvement opportunity. The same analysis that informs a single deal can be applied across a portfolio to identify which entities have the most meaningful rate upside and sequence renegotiations accordingly.

What this data cannot tell you

Payor rate due diligence is powerful but has limits worth naming honestly. The data tells you what rates exist — it does not guarantee those rates can be replicated for a specific practice post-acquisition. Factors like network adequacy, provider relationships, and local market dynamics all influence how negotiations play out. The analysis is a starting point for an informed conversation, not a guaranteed outcome.

It is also worth noting that very small practices, highly specialized providers, or practices in markets with limited competition may have rate dynamics that do not fit neatly into a benchmarking framework. The analysis is most powerful for mid-to-large group acquisitions in competitive markets — which is precisely where most of the M&A activity in specialty healthcare is concentrated.

How to incorporate this into your diligence process

The most effective approach is to run the payor rate analysis in parallel with financial and operational diligence — not after. Rate position is a fundamental driver of normalized EBITDA, and discovering a significant rate gap late in a process can reopen deal economics at a point where that is expensive for everyone.

Early-stage screening — even a high-level look at rate position for a potential target — can help prioritize where to spend more intensive diligence resources and identify deals where the rate improvement thesis is realistic versus aspirational.